Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 4 (2007), Issue 5 (May)

1. Effects of human leukocyte antigen class I genetic parameters on clinical outcomes and survival after initiation of highly active antiretroviral therapy.
   J Infect Dis, 195(11): 1694-704. [Abstract] [Full-text]
2. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.
   J Clin Oncol, 25(13): 1670-6. [Abstract] [Full-text]
3. Phase II trial of infusional fluorouracil, leucovorin, mitomycin, and dipyridamole in locally advanced unresectable pancreatic adenocarcinoma: SWOG S9700.
   J Clin Oncol, 25(13): 1665-9. [Abstract] [Full-text]
4. Neutropenic events in community practices reduced by first and subsequent cycle pegfilgrastim use.
   Oncologist, 12(4): 484-94. [Abstract] [Full-text]
5. Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients.
   Oncologist, 12(4): 478-83. [Abstract] [Full-text]
6. Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature.
   Oncologist, 12(4): 451-64. [Abstract] [Full-text]
7. BAC clones related to prognosis in patients with esophageal squamous carcinoma: an array comparative genomic hybridization study.
   Oncologist, 12(4): 406-17. [Abstract] [Full-text]
8. Pharmacodiagnostics and targeted therapies - a rational approach for individualizing medical anticancer therapy in breast cancer.
   Oncologist, 12(4): 397-405. [Abstract] [Full-text]
9. Achieving higher pathological complete response rates in HER-2-positive patients with induction chemotherapy without trastuzumab in operable breast cancer.
   Oncologist, 12(4): 390-6. [Abstract] [Full-text]
10. Capecitabine in combination with novel targeted agents in the management of metastatic breast cancer: underlying rationale and results of clinical trials.
    Oncologist, 12(4): 375-89. [Abstract] [Full-text]
11. Local cytokine levels associated with delayed-type hypersensitivity responses: modulation by gender, ovariectomy, and estrogen replacement.
    J Endocrinol, 193(2): 291-7. [Abstract] [Full-text]
12. 3,3',5-Triiodo-L-thyronine inhibits ductal pancreatic adenocarcinoma proliferation improving the cytotoxic effect of chemotherapy.
    J Endocrinol, 193(2): 209-23. [Abstract] [Full-text]
13. Acute tumour lysis syndrome in a dog with B-Cell multicentric lymphoma.
    Aust Vet J, 85(5): 206-8. [Abstract] [Full-text]
14. A randomized trial of telephone psychotherapy and pharmacotherapy for depression: continuation and durability of effects.
    J Consult Clin Psychol, 75(2): 257-66. [Abstract] [Full-text]
15. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B.
    J Clin Oncol, 25(13): 1698-704. [Abstract] [Full-text]
16. Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623.
    J Clin Oncol, 25(13): 1677-82. [Abstract] [Full-text]
17. Health-related quality of life in younger patients with chronic lymphocytic leukemia treated with fludarabine plus cyclophosphamide or fludarabine alone for first-line therapy: a study by the German CLL Study Group.
    J Clin Oncol, 25(13): 1722-31. [Abstract] [Full-text]
18. Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer.
    J Surg Oncol, 95(6): 507-12. [Abstract] [Full-text]
19. Antibiotic prophylaxis in cochlear implant surgery.
    Laryngoscope, 117(5): 864-7. [Abstract] [Full-text]
20. Phase II study of gemcitabine and cisplatin in patients with previously untreated extensive stage small cell lung cancer: Southwest Oncology Group Study 9718.
    J Thorac Oncol, 2(5): 440-4. [Abstract] [Full-text]
21. EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).
    J Thorac Oncol, 2(5): 423-9. [Abstract] [Full-text]
22. The rationale for adjuvant chemotherapy in stage I non-small cell lung cancer.
    J Thorac Oncol, 2(5): 377-83. [Abstract] [Full-text]
23. Hirudin treatment for multiple thromboses in a preterm infant with inherited thrombophilia.
    Blood Coagul Fibrinolysis, 18(4): 381-3. [Abstract] [Full-text]
24. An adaptive multimeme algorithm for designing HIV multidrug therapies.
    IEEE/ACM Trans Comput Biol Bioinform, 4(2): 264-78. [Abstract] [Full-text]
25. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens.
    Clin Cancer Res, 13(9): 2751-7. [Abstract] [Full-text]
26. Pulsed-high intensity focused ultrasound and low temperature-sensitive liposomes for enhanced targeted drug delivery and antitumor effect.
    Clin Cancer Res, 13(9): 2722-7. [Abstract] [Full-text]
27. A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors.
    Clin Cancer Res, 13(9): 2692-8. [Abstract] [Full-text]
28. Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer.
    Clin Cancer Res, 13(9): 2684-91. [Abstract] [Full-text]
29. Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer.
    Clin Cancer Res, 13(9): 2675-83. [Abstract] [Full-text]
30. Phase I and pharmacokinetic study of 7-hydroxystaurosporine and carboplatin in advanced solid tumors.
    Clin Cancer Res, 13(9): 2667-74. [Abstract] [Full-text]
31. Locally administered antibiotics for prophylaxis against surgical wound infection. An in vivo study.
    J Bone Joint Surg Am, 89(5): 929-33. [Abstract] [Full-text]
32. Managing complex medication regimens: perspectives of consumers with osteoarthritis and healthcare professionals.
    Ann Pharmacother, 41(5): 764-71. [Abstract] [Full-text]
33. Hospital-based directly observed therapy for HIV-infected children and adolescents to assess adherence to antiretroviral medications.
    Pediatrics, 119(5): e1142-8. [Abstract] [Full-text]
34. Biodegradable nanogels prepared by atom transfer radical polymerization as potential drug delivery carriers: synthesis, biodegradation, in vitro release, and bioconjugation.
    J Am Chem Soc, 129(18): 5939-45. [Abstract] [Full-text]
35. A novel trans-lymphatic drug delivery system: implantable gelatin sponge impregnated with PLGA-paclitaxel microspheres.
    Biomaterials, 28(21): 3236-44. [Abstract] [Full-text]
36. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    BMC Cancer, 7: 63. [Abstract] [Full-text]
37. Solitary extramedullary plasmacytoma of the canine larynx.
    J Small Anim Pract, 48(5): 288-91. [Abstract] [Full-text]
38. Long-term follow-up of 414 HIV-infected Romanian children and adolescents receiving lopinavir/ritonavir-containing highly active antiretroviral therapy.
    Pediatrics, 119(5): e1116-20. [Abstract] [Full-text]
39. Surgical resection of persistent pulmonary fungus nodules and secondary prophylaxis are effective in preventing fungal relapse in patients receiving chemotherapy or bone marrow transplantation for leukemia.
    Bone Marrow Transplant, 39(10): 631-5. [Abstract] [Full-text]
40. Geranylgeranyltransferase I as a target for anti-cancer drugs.
    J Clin Invest, 117(5): 1223-5. [Abstract] [Full-text]
41. Options for hormone therapy in women who have had a hysterectomy.
    Menopause, 14(3): 592-7; quiz 598-9. [Abstract] [Full-text]
42. Surgical versus natural menopause: cognitive issues.
    Menopause, 14(3): 572-9. [Abstract] [Full-text]
43. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting.
    J Nucl Med, 48(5): 736-43. [Abstract] [Full-text]
44. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).
    Cancer, 109(10): 2068-76. [Abstract] [Full-text]
45. Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma.
    Cancer, 109(10): 2132-41. [Abstract] [Full-text]
46. The impact on survival of thromboembolic phenomena occurring before and during protocol chemotherapy in patients with advanced gastroesophageal adenocarcinoma.
    Cancer, 109(10): 1989-95. [Abstract] [Full-text]
47. Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients.
    Cancer, 109(10): 2077-82. [Abstract] [Full-text]
48. Molecular analysis of human endometrium: short-term tibolone signaling differs significantly from estrogen and estrogen + progestagen signaling.
    J Mol Med, 85(5): 471-80. [Abstract] [Full-text]
49. Bridging the gap between antiretroviral access and adherence in Mexico.
    Qual Health Res, 17(5): 599-611. [Abstract] [Full-text]
50. Programmed drug delivery: nanosystems for tumor targeting.
    Expert Opin Biol Ther, 7(5): 587-93. [Abstract] [Full-text]
51. Computer-based insulin infusion protocol improves glycemia control over manual protocol.
    J Am Med Inform Assoc, 14(3): 278-87. [Abstract] [Full-text]
52. Limited prognostic value of noninvasive assessment of reperfusion by continuous vectorcardiography in an unselected cohort of patients with acute ST-elevation myocardial infarction treated with thrombolysis.
    J Electrocardiol, 40(3): 305-10. [Abstract] [Full-text]
53. The management of superficial bladder cancer.
    Nat Clin Pract Urol, 4(5): 254-60. [Abstract] [Full-text]
54. A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy.
    Cancer Res, 67(9): 4474-81. [Abstract] [Full-text]
55. Bexarotene (LGD1069, Targretin), a selective retinoid X receptor agonist, prevents and reverses gemcitabine resistance in NSCLC cells by modulating gene amplification.
    Cancer Res, 67(9): 4425-33. [Abstract] [Full-text]
56. Thermal cycling enhances the accumulation of a temperature-sensitive biopolymer in solid tumors.
    Cancer Res, 67(9): 4418-24. [Abstract] [Full-text]
57. Regression of lung and colon cancer xenografts by depleting or inhibiting RLIP76 (Ral-binding protein 1).
    Cancer Res, 67(9): 4382-9. [Abstract] [Full-text]
58. Successful treatment of primary cardiac lymphoma by rituximab-CHOP and high-dose chemotherapy with autologous peripheral blood stem cell transplantation.
    Int J Hematol, 85(3): 264-6. [Abstract] [Full-text]
59. Bacterial bloodstream infection in neutropenic adult patients after myeloablative cord blood transplantation: experience of a single institution in Japan.
    Int J Hematol, 85(3): 238-41. [Abstract] [Full-text]
60. Prescription of prophylactic antibiotics for neurosurgical procedures in teaching hospitals in Iran.
    Am J Infect Control, 35(4): 260-2. [Abstract] [Full-text]
61. Safety of pleurodesis with talc poudrage in malignant pleural effusion: a prospective cohort study.
    Lancet, 369(9572): 1535-9. [Abstract] [Full-text]
62. Metastatic intratesticular alveolar rhabdomyosarcoma discovered after induction of systemic chemotherapy.
    Urology, 69(5): 982.e13-5. [Abstract] [Full-text]
63. Bacterially derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeutics.
    Cancer Cell, 11(5): 431-45. [Abstract] [Full-text]
64. Uganda: delivering analgesia in rural Africa: opioid availability and nurse prescribing.
    J Pain Symptom Manage, 33(5): 547-51. [Abstract] [Full-text]
65. Antithrombotic therapy and endovascular stents are effective treatment for blunt carotid injuries: results from longterm followup.
    J Am Coll Surg, 204(5): 1007-13; discussion 1014-5. [Abstract] [Full-text]
66. Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents.
    J Am Coll Surg, 204(5): 753-61; discussion 761-3. [Abstract] [Full-text]
67. Eliminating error-prone notations in medical communications.
    Expert Opin Drug Saf, 6(3): 233-4. [Abstract] [Full-text]
68. Drugs in the elderly--more good than harm?
    Expert Opin Drug Saf, 6(3): 229-31. [Abstract] [Full-text]
69. Metabotropic glutamate receptors: new targets for the control of tumor growth?
    Trends Pharmacol Sci, 28(5): 206-13. [Abstract] [Full-text]
70. PPAR-gamma: therapeutic target for ischemic stroke.
    Trends Pharmacol Sci, 28(5): 244-9. [Abstract] [Full-text]
71. Repackaged pharmaceuticals in the California workers' compensation system: from distribution and pricing options to physician and retail dispensing.
    Am J Ind Med, 50(4): 303-15. [Abstract] [Full-text]
72. Rehydration with fluid of varying tonicities: effects on fluid regulatory hormones and exercise performance in the heat.
    J Appl Physiol, 102(5): 1899-905. [Abstract] [Full-text]
73. Popliteal artery aneurysm with acute ischemia in 229 patients. Outcome after thrombolytic and surgical therapy.
    Eur J Vasc Endovasc Surg, 33(6): 690-5. [Abstract] [Full-text]
74. Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting.
    Blood, 109(10): 4171-3. [Abstract] [Full-text]
75. A new approach to diabetic control: fuzzy logic and insulin pump technology.
    Med Eng Phys, 29(7): 824-7. [Abstract] [Full-text]
76. Effects of new drugs on overall health spending: Frank Lichtenberg responds.
    Health Aff (Millwood), 26(3): 887-90. [Abstract] [Full-text]
77. Do newer prescription drugs pay for themselves? A reassessment of the evidence.
    Health Aff (Millwood), 26(3): 880-6. [Abstract] [Full-text]
78. Consumers' preferences for the communication of risk information in drug advertising.
    Health Aff (Millwood), 26(3): 863-70. [Abstract] [Full-text]
79. What's more dangerous, your aspirin or your car? Thinking rationally about drug risks (and benefits).
    Health Aff (Millwood), 26(3): 636-46. [Abstract] [Full-text]
80. Short- and long-term complications of therapy for testicular cancer.
    Urol Clin North Am, 34(2): 259-68; abstract xi. [Abstract] [Full-text]
81. Chemotherapy for good-risk germ cell tumors: current concepts and controversies.
    Urol Clin North Am, 34(2): 171-7; abstract viii-ix. [Abstract] [Full-text]
82. Ultrasound-enhanced Thrombolysis.
    J Endovasc Ther, 14(2): 251-6. [Abstract] [Full-text]
83. The regenerative effects of platelet-rich plasma on meniscal cells in vitro and its in vivo application with biodegradable gelatin hydrogel.
    Tissue Eng, 13(5): 1103-12. [Abstract] [Full-text]
84. Nanohydroxyapatite microspheres as delivery system for antibiotics: release kinetics, antimicrobial activity, and interaction with osteoblasts.
    J Biomed Mater Res A, 81(4): 994-1004. [Abstract] [Full-text]
85. Novel thermosensitive polymeric micelles for docetaxel delivery.
    J Biomed Mater Res A, 81(4): 847-57. [Abstract] [Full-text]
86. Photodynamic therapy of malignant biliary strictures using meso-tetrahydroxyphenylchlorin.
    Eur J Gastroenterol Hepatol, 19(6): 479-85. [Abstract] [Full-text]
87. Lymphoma in older patients.
    J Clin Oncol, 25(14): 1916-23. [Abstract] [Full-text]
88. Adjuvant therapy in the elderly: making the right decision.
    J Clin Oncol, 25(14): 1870-5. [Abstract] [Full-text]
89. The effects of short-term hormone replacement therapy on long-term bone mineral density.
    Climacteric, 10(3): 257-63. [Abstract] [Full-text]
90. Neutral effect of ultra-low-dose continuous combined estradiol and norethisterone acetate on mammographic breast density.
    Climacteric, 10(3): 249-56. [Abstract] [Full-text]
91. Number of women needed in a prospective trial to prove potential cardiovascular benefit of hormone replacement therapy.
    Climacteric, 10(3): 238-43. [Abstract] [Full-text]
92. Distinct lipid/lipoprotein profiles and hormonal responsiveness in nine ethnic groups of postmenopausal Asian women: the Pan-Asia Menopause (PAM) study.
    Climacteric, 10(3): 225-37. [Abstract] [Full-text]
93. Women's needs for CAM information to manage menopausal symptoms.
    Climacteric, 10(3): 215-24. [Abstract] [Full-text]
94. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society.
    Menopause, 14(3): 355-69; quiz 370-1. [Abstract] [Full-text]
95. Decline in use of hormone therapy among postmenopausal women in the United Kingdom.
    Menopause, 14(3): 462-7. [Abstract] [Full-text]
96. Effect of ultra-low-dose transdermal estradiol on breast density in postmenopausal women.
    Menopause, 14(3): 391-6. [Abstract] [Full-text]
97. Levonorgestrel-releasing intrauterine system as an adjunct to estrogen for the treatment of menopausal symptoms--a review.
    Menopause, 14(3): 550-4. [Abstract] [Full-text]
98. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma.
    Blood, 109(7): 2767-72. [Abstract] [Full-text]
99. Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON).
    Blood, 109(7): 2759-66. [Abstract] [Full-text]
100. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients.
     Blood, 109(7): 2773-80. [Abstract] [Full-text]
101. Psychotropic prescriptions in a sample including both healthy and mood and disruptive disordered preschoolers: relationships to diagnosis, impairment, prescriber type, and assessment methods.
     J Child Adolesc Psychopharmacol, 17(2): 205-15. [Abstract] [Full-text]
102. Chronotherapy in hypertensive patients: administration-time dependent effects of treatment on blood pressure regulation.
     Expert Rev Cardiovasc Ther, 5(3): 463-75. [Abstract] [Full-text]
103. Zinc supplementation reduced cost and duration of acute diarrhea in children.
     J Clin Epidemiol, 60(6): 560-6. [Abstract] [Full-text]
104. Home intravenous antimicrobial infusion therapy: a viable option in older adults.
     J Am Geriatr Soc, 55(5): 645-50. [Abstract] [Full-text]
105. Primary CNS lymphoma.
     Expert Rev Anticancer Ther, 7(5): 689-700. [Abstract] [Full-text]
106. Pemetrexed in small-cell lung cancer: background and review of the ongoing GALES pivotal trial.
     Expert Rev Anticancer Ther, 7(5): 635-40. [Abstract] [Full-text]
107. ABCG1--a potential therapeutic target for atherosclerosis.
     Med Hypotheses, 69(1): 214-7. [Abstract] [Full-text]
108. Phase II study of biweekly administration of docetaxel and irinotecan in patients with refractory or relapsed advanced non-small cell lung cancer.
     Cancer Chemother Pharmacol, 60(2): 267-74. [Abstract] [Full-text]
109. Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial.
     Cancer Chemother Pharmacol, 60(2): 295-303. [Abstract] [Full-text]
110. The efficacy and relationship between peak concentration and toxicity profile of fixed-dose-rate gemcitabine plus carboplatin in patients with advanced non-small-cell lung cancer.
     Cancer Chemother Pharmacol, 60(2): 211-8. [Abstract] [Full-text]
111. Phase II study of weekly chemotherapy with paclitaxel and gemcitabine as second-line treatment for advanced non-small cell lung cancer after treatment with platinum-based chemotherapy.
     Cancer Chemother Pharmacol, 60(2): 189-95. [Abstract] [Full-text]
112. Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results.
     Int J Radiat Oncol Biol Phys, 68(2): 472-8. [Abstract] [Full-text]
113. Carcinoid heart disease.
     Prog Cardiovasc Dis, 49(6): 439-51. [Abstract] [Full-text]
114. Stroke thrombolysis 2006: an update progress in cardiovascular diseases.
     Prog Cardiovasc Dis, 49(6): 430-8. [Abstract] [Full-text]
115. Canadian Society for the Study of the Aging Male: response to health Canada's position paper on testosterone treatment.
     J Sex Med, 4(3): 558-66. [Abstract] [Full-text]
116. Fast-dissolving tablets of glyburide based on ternary solid dispersions with PEG 6000 and surfactants.
     Drug Deliv, 14(4): 247-55. [Abstract] [Full-text]
117. Stability of vitamins C and E in topical microemulsions for combined antioxidant therapy.
     Drug Deliv, 14(4): 235-45. [Abstract] [Full-text]
118. Controlled release of methotrexate from w/o microemulsion and its in vitro antitumor activity.
     Drug Deliv, 14(4): 225-33. [Abstract] [Full-text]
119. Preparation, characterization and pharmacokinetics of liposomes-encapsulated cyclodextrins inclusion complexes for hydrophobic drugs.
     Drug Deliv, 14(4): 201-8. [Abstract] [Full-text]
120. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
     Oncogene, 26(22): 3291-310. [Abstract] [Full-text]
121. Medication history reconciliation by pharmacists in an inpatient behavioral health unit.
     Am J Health Syst Pharm, 64(10): 1087-91. [Abstract] [Full-text]
122. Characterization of prescribing errors in an internal medicine clinic.
     Am J Health Syst Pharm, 64(10): 1062-70. [Abstract] [Full-text]
123. Photodynamic therapy using verteporfin photosensitization in the pancreas and surrounding tissues in the Syrian golden hamster.
     Pancreatology, 7(1): 20-7. [Abstract] [Full-text]
124. Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis.
     Cancer, 109(8): 1543-9. [Abstract] [Full-text]
125. Octreotide alone or in combination with rofecoxib as palliative treatment for advanced hepatocellular cancer.
     Z Gastroenterol, 45(5): 369-77. [Abstract] [Full-text]
126. The contrast enema for Hirschsprung disease: predictors of a false-positive result.
     J Pediatr Surg, 42(5): 792-5. [Abstract] [Full-text]
127. Joint effect of dopaminergic genes on likelihood of smoking following treatment with bupropion SR.
     Health Psychol, 26(3): 361-8. [Abstract] [Full-text]
128. Protective effect of an acute oral loading dose of trimetazidine on myocardial injury following percutaneous coronary intervention.
     Heart, 93(6): 703-7. [Abstract] [Full-text]
129. A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer.
     Br J Cancer, 96(10): 1514-9. [Abstract] [Full-text]
130. Effect of zoledronic acid on the doxycycline-induced decrease in tumour burden in a bone metastasis model of human breast cancer.
     Br J Cancer, 96(10): 1526-31. [Abstract] [Full-text]
131. Combination treatment with Grb7 peptide and Doxorubicin or Trastuzumab (Herceptin) results in cooperative cell growth inhibition in breast cancer cells.
     Br J Cancer, 96(10): 1520-5. [Abstract] [Full-text]
132. Strategies for coping in a complex world: adherence behavior among older adults with chronic illness.
     J Gen Intern Med, 22(6): 805-10. [Abstract] [Full-text]
133. The demise of Oregon's Medically Needy program: effects of losing prescription drug coverage.
     J Gen Intern Med, 22(6): 847-51. [Abstract] [Full-text]
134. Trimetazidine in the prevention of contrast-induced nephropathy after coronary procedures.
     Heart, 93(6): 698-702. [Abstract] [Full-text]
135. Endostatin plus interferon-alpha2b therapy for metastatic melanoma: a novel combination of antiangiogenic and immunomodulatory agents.
     Melanoma Res, 17(3): 193-200. [Abstract] [Full-text]
136. Recombinant interferon alpha-2b and coenzyme Q10 as a postsurgical adjuvant therapy for melanoma: a 3-year trial with recombinant interferon-alpha and 5-year follow-up.
     Melanoma Res, 17(3): 177-83. [Abstract] [Full-text]
137. Following anterior resection for rectal cancer, defunctioning ileostomy closure may be significantly delayed by adjuvant chemotherapy: a retrospective study.
     Colorectal Dis, 9(5): 420-2. [Abstract] [Full-text]
138. Novel therapeutic targets for the treatment of Fabry disease.
     Expert Opin Ther Targets, 11(6): 821-33. [Abstract] [Full-text]
139. Lysine-specific demethylase 1 as a potential therapeutic target.
     Expert Opin Ther Targets, 11(6): 809-20. [Abstract] [Full-text]
140. Downstream intracellular effectors of epidermal growth factor receptor as targets for anticancer therapy.
     Expert Opin Ther Targets, 11(6): 771-82. [Abstract] [Full-text]
141. Targeting Helicobacter pylori in gastric carcinogenesis.
     Expert Opin Ther Targets, 11(6): 757-69. [Abstract] [Full-text]
142. Retinoid-related orphan receptor gamma t is a potential therapeutic target for controlling inflammatory autoimmunity.
     Expert Opin Ther Targets, 11(6): 737-43. [Abstract] [Full-text]
143. Cell adhesion and cancer: is there a potential for therapeutic intervention?
     Expert Opin Ther Targets, 11(6): 727-31. [Abstract] [Full-text]
144. Gender distribution of adult patients on highly active antiretroviral therapy (HAART) in Southern Africa: a systematic review.
     BMC Public Health, 7: 63. [Abstract] [Full-text]
145. Enteral drugs given through a central venous catheter.
     Anaesthesia, 62(6): 624-6. [Abstract] [Full-text]
146. Inadvertent epidural administration of insulin.
     Anaesthesia, 62(6): 621-3. [Abstract] [Full-text]
147. Intravenous infusions in hyperbaric chambers: effect of compression on syringe function.
     Anaesthesia, 62(6): 602-4. [Abstract] [Full-text]
148. Microbial growth in propofol formulations with disodium edetate and the influence of venous access system dead space.
     Anaesthesia, 62(6): 575-80. [Abstract] [Full-text]
149. Short communication: Immune reconstitution after autologous peripheral blood stem cell transplantation in HIV-infected patients: might be better than expected?
     AIDS Res Hum Retroviruses, 23(4): 543-8. [Abstract] [Full-text]
150. Quality of life of Chinese patients with ovarian malignancies during chemotherapy under condition of no recurrence.
     Cancer Nurs, 30(3): 243-51. [Abstract] [Full-text]
151. Survivin, a member of the inhibitor of apoptosis family, is induced by photodynamic therapy and is a target for improving treatment response.
     Cancer Res, 67(10): 4989-95. [Abstract] [Full-text]
152. The farnesyltransferase inhibitor R115777 up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer cells.
     Cancer Res, 67(10): 4973-80. [Abstract] [Full-text]
153. Comparison of cardiac outputs during major surgery using the Deltex CardioQ oesophageal Doppler monitor and the Novametrix-Respironics NICO: a prospective observational study.
     Int J Surg, 5(3): 176-82. [Abstract] [Full-text]
154. Solid lipid nanoparticles: could they help to improve the efficacy of pharmacologic treatments for brain tumors?
     Neurol Res, 29(3): 324-30. [Abstract] [Full-text]
155. High coverage with HAART is required to substantially reduce the number of deaths from tuberculosis: system dynamics simulation.
     Int J STD AIDS, 18(4): 267-73. [Abstract] [Full-text]
156. Changes of the prescription of hormone therapy in menopausal women: an observational study in Taiwan.
     BMC Public Health, 7: 56. [Abstract] [Full-text]
157. Rapid progression of carotid lesions in HAART-treated HIV-1 patients.
     Atherosclerosis, 192(2): 407-12. [Abstract] [Full-text]
158. Protein direct delivery to dendritic cells using nanoparticles based on amphiphilic poly(amino acid) derivatives.
     Biomaterials, 28(23): 3427-36. [Abstract] [Full-text]
159. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system.
     J Clin Oncol, 25(15): 2127-32. [Abstract] [Full-text]
160. Obesity and outcome in pediatric acute lymphoblastic leukemia.
     J Clin Oncol, 25(15): 2063-9. [Abstract] [Full-text]
161. Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children's Oncology Group.
     J Clin Oncol, 25(15): 2057-62. [Abstract] [Full-text]
162. Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14.
     J Clin Oncol, 25(15): 2012-8. [Abstract] [Full-text]
163. Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma.
     J Clin Oncol, 25(15): 1974-8. [Abstract] [Full-text]
164. The effect of an interactive visual reminder in an anesthesia information management system on timeliness of prophylactic antibiotic administration.
     Anesth Analg, 104(6): 1462-6, table of contents. [Abstract] [Full-text]
165. Therapy-related, mixed-lineage leukaemia translocation-positive, monoblastic myeloid sarcoma of the uterus.
     J Clin Pathol, 60(5): 562-4. [Abstract] [Full-text]
166. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.
     Lancet, 369(9574): 1711-23. [Abstract] [Full-text]
167. Ovarian cancer and hormone replacement therapy in the Million Women Study.
     Lancet, 369(9574): 1703-10. [Abstract] [Full-text]
168. Use of over-the-counter malaria medicines in children and adults in three districts in Kenya: implications for private medicine retailer interventions.
     Malar J, 6: 57. [Abstract] [Full-text]
169. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.
     J Clin Oncol, 25(15): 1960-6. [Abstract] [Full-text]
170. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17.
     J Clin Oncol, 25(15): 2006-11. [Abstract] [Full-text]
171. Towards controlled release of BDNF--manufacturing strategies for protein-loaded lipid implants and biocompatibility evaluation in the brain.
     J Control Release, 119(2): 163-72. [Abstract] [Full-text]
172. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study.
     J Clin Oncol, 25(15): 1986-92. [Abstract] [Full-text]
173. Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma.
     J Clin Oncol, 25(15): 2000-5. [Abstract] [Full-text]
174. Influence of wettability and surface activity on release behavior of hydrophilic substances from lipid matrices.
     J Control Release, 119(2): 173-81. [Abstract] [Full-text]
175. Target-specific intracellular delivery of siRNA using degradable hyaluronic acid nanogels.
     J Control Release, 119(2): 245-52. [Abstract] [Full-text]
176. Future of toxicology--iron chelators and differing modes of action and toxicity: the changing face of iron chelation therapy.
     Chem Res Toxicol, 20(5): 715-20. [Abstract] [Full-text]
177. The lack of significance of Ca125 response in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking.
     Gynecol Oncol, 105(3): 712-5. [Abstract] [Full-text]
178. PLGA nanoparticles for oral delivery of cyclosporine: nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral.
     J Control Release, 119(2): 197-206. [Abstract] [Full-text]
179. Delivery of G3139 using releasable PEG-linkers: impact on pharmacokinetic profile and anti-tumor efficacy.
     J Control Release, 119(2): 143-52. [Abstract] [Full-text]
180. Carcinosarcoma of the ovary treated with platinum and taxane: the memorial Sloan-Kettering Cancer Center experience.
     Gynecol Oncol, 105(3): 657-61. [Abstract] [Full-text]
181. A phase I study of paclitaxel, topotecan, cisplatin and Filgrastim in patients with newly diagnosed advanced ovarian epithelial malignancies: a Gynecologic Oncology Group study.
     Gynecol Oncol, 105(3): 667-71. [Abstract] [Full-text]
182. Intraperitoneal chemotherapy for patients with advanced ovarian cancer: a review of the evidence and standards for the delivery of care.
     Gynecol Oncol, 105(3): 747-56. [Abstract] [Full-text]
183. Unexpected long-term survival without evidence of disease after salvage chemotherapy for recurrent metastatic cervical cancer: a case series.
     Gynecol Oncol, 105(3): 823-5. [Abstract] [Full-text]
184. Effects of castration and hormone replacement on male sexual behavior and pattern of expression in the brain of sex-steroid receptors in BALB/c AnN mice.
     Comp Biochem Physiol A Mol Integr Physiol, 147(3): 607-15. [Abstract] [Full-text]
185. Medical management of urinary stone disease.
     Expert Opin Pharmacother, 8(8): 1117-25. [Abstract] [Full-text]
186. Compared benefit of approved and experimental immunosuppressive therapeutic approaches in multiple sclerosis.
     Expert Opin Pharmacother, 8(8): 1103-16. [Abstract] [Full-text]
187. Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study.
     Clin Infect Dis, 44(12): 1625-31. [Abstract] [Full-text]
188. A refill adherence algorithm for multiple short intervals to estimate refill compliance (ReComp).
     Med Care, 45(6): 497-504. [Abstract] [Full-text]
189. Accuracy of serial National Institutes of Health Stroke Scale scores to identify artery status in acute ischemic stroke.
     Circulation, 115(20): 2660-5. [Abstract] [Full-text]
190. Managing Medicare's HIV caseload in the era of suppressive therapy.
     Am J Public Health, 97(6): 1053-9. [Abstract] [Full-text]
191. Directly observed highly active antiretroviral therapy for HIV-infected children in Cambodia.
     Am J Public Health, 97(6): 974-7. [Abstract] [Full-text]
192. Rectal cancer: MR imaging before neoadjuvant chemotherapy and radiation therapy for prediction of tumor-free circumferential resection margins and long-term survival.
     Radiology, 243(3): 744-51. [Abstract] [Full-text]
193. The role of nuclear receptors in pharmacokinetic drug-drug interactions in oncology.
     Cancer Treat Rev, 33(4): 369-80. [Abstract] [Full-text]
194. Highly active antiretroviral therapy of cognitive dysfunction and neuronal abnormalities in SCID mice with HIV encephalitis.
     Exp Neurol, 205(2): 506-12. [Abstract] [Full-text]
195. Chemotherapy of advanced gastric cancer.
     Cancer Treat Rev, 33(4): 315-24. [Abstract] [Full-text]
196. Combined flow cytometry and confocal laser scanning microscopy for evaluation of BR96 antibody cancer cell targeting and internalization.
     Cytometry A, 71(6): 361-70. [Abstract] [Full-text]
197. Fluid therapy for children: facts, fashions and questions.
     Arch Dis Child, 92(6): 546-50. [Abstract] [Full-text]
198. Internal reporting system to improve a pharmacy's medication distribution process.
     Am J Health Syst Pharm, 64(11): 1197-202. [Abstract] [Full-text]
199. Educational interventions to reduce use of unsafe abbreviations.
     Am J Health Syst Pharm, 64(11): 1170-3. [Abstract] [Full-text]
200. The quality of molecular response to chemotherapy is predictive for the outcome of AML1-ETO-positive AML and is independent of pretreatment risk factors.
     Leukemia, 21(6): 1177-82. [Abstract] [Full-text]
201. Nicotinic alpha 7 receptors as a new target for treatment of cannabis abuse.
     J Neurosci, 27(21): 5615-20. [Abstract] [Full-text]
202. Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia.
     Cancer, 109(11): 2291-8. [Abstract] [Full-text]
203. Microenvironmental pH modulation in solid dosage forms.
     J Pharm Sci, 96(5): 948-59. [Abstract] [Full-text]
204. Fluid support worsens outcome and negates the benefit of protective antigen-directed monoclonal antibody in a lethal toxin-infused rat Bacillus anthracis shock model.
     Crit Care Med, 35(6): 1560-7. [Abstract] [Full-text]
205. Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial.
     Cancer, 109(9): 1863-9. [Abstract] [Full-text]
206. Imatinib mesylate for targeting the platelet-derived growth factor beta receptor in combination with fluorouracil and leucovorin in patients with refractory pancreatic, bile duct, colorectal, or gastric cancer--a dose-escalation Phase I trial.
     Cancer, 109(9): 1897-904. [Abstract] [Full-text]
207. Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma.
     Cancer, 109(9): 1799-803. [Abstract] [Full-text]
208. Adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided platinum-based 2-drug chemotherapy for unresectable nonsmall-cell lung cancer.
     Cancer, 109(9): 1829-35. [Abstract] [Full-text]
209. Phase II trial of irinotecan and cisplatin with early concurrent radiotherapy in limited-disease small-cell lung cancer.
     Cancer, 109(9): 1845-950. [Abstract] [Full-text]
210. Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study.
     Cancer, 109(9): 1905-13. [Abstract] [Full-text]
211. Phase II randomized study of daily gefitinib treatment alone or with vinorelbine every 2 weeks in patients with adenocarcinoma of the lung who failed at least 2 regimens of chemotherapy.
     Cancer, 109(9): 1821-8. [Abstract] [Full-text]
212. The role of adherence to antiretroviral therapy in the management of HIV infection.
     J Acquir Immune Defic Syndr, 45: S14-8. [Abstract] [Full-text]
213. Volume replacement therapy during major orthopedic surgery using Voluven (hydroxyethyl starch 130/0.4) or hetastarch.
     Anesthesiology, 106(6): 1120-7. [Abstract] [Full-text]
214. Discontinuation of non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy due to nucleoside analogue reverse transcriptase inhibitor-related metabolic toxicity.
     Int J STD AIDS, 18(5): 343-6. [Abstract] [Full-text]
215. A comparison of two methods of partner notification for sexually transmitted infections in South Africa: patient-delivered partner medication and patient-based partner referral.
     Int J STD AIDS, 18(5): 338-40. [Abstract] [Full-text]
216. Sexually transmitted disease symptom management behaviours among female sex workers in Tashkent, Uzbekistan.
     Int J STD AIDS, 18(5): 324-8. [Abstract] [Full-text]
217. Experiential learning as part of pharmacist supplementary prescribing training: feedback from trainees and their mentors.
     Ann Pharmacother, 41(6): 1031-8. [Abstract] [Full-text]
218. Central retinal sensitivity measured with the micro perimeter 1 after photodynamic therapy for polypoidal choroidal vasculopathy.
     Am J Ophthalmol, 143(6): 984-994. [Abstract] [Full-text]
219. Cancer chemotherapy impairs contextual but not cue-specific fear memory.
     Behav Brain Res, 181(1): 168-72. [Abstract] [Full-text]
220. Who gains most? A 10-year experience with 611 thoracoscopic talc pleurodeses.
     Ann Thorac Surg, 83(6): 1940-5. [Abstract] [Full-text]
221. Quantitative longitudinal analysis of T cell receptor repertoire expression in HIV-infected patients on antiretroviral and interleukin-2 therapy.
     AIDS Res Hum Retroviruses, 23(5): 741-7. [Abstract] [Full-text]
222. Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): a Southwest Oncology Group Phase II study.
     Cancer Invest, 25(3): 182-8. [Abstract] [Full-text]
223. Time factor in radiotherapy and chemotherapy for limited disease small-cell lung cancer.
     Cancer Invest, 25(3): 163-71. [Abstract] [Full-text]
224. A Phase I dose-finding study using an innovative sequential biweekly schedule of irinotecan followed 24 hours later by capecitabine.
     Cancer Invest, 25(3): 148-53. [Abstract] [Full-text]
225. Randomized Phase II trial of thalidomide alone versus thalidomide plus interferon alpha in patients with refractory multiple myeloma.
     Cancer Invest, 25(3): 140-7. [Abstract] [Full-text]
226. Randomized clinical trial of single- versus multiple-dose antimicrobial prophylaxis in gastric cancer surgery.
     Br J Surg, 94(6): 683-8. [Abstract] [Full-text]
227. Multicentre randomized clinical trial of mechanical bowel preparation in elective colonic resection.
     Br J Surg, 94(6): 689-95. [Abstract] [Full-text]
228. A functionalized 20-residue peptaibol derivative for nucleic acid delivery.
     Chem Biodivers, 4(5): 991-7. [Abstract] [Full-text]
229. Enhanced pharmacological activity of recombinant human interleukin-11 (rhIL11) by chemical modification with polyethylene glycol.
     J Control Release, 119(3): 271-8. [Abstract] [Full-text]
230. Formulation and in vitro characterization of an in situ gelable, photo-polymerizable Pluronic hydrogel suitable for injection.
     J Control Release, 119(3): 313-9. [Abstract] [Full-text]
231. Evaluation of polyamidoamine dendrimer/alpha-cyclodextrin conjugate (generation 3, G3) as a novel carrier for small interfering RNA (siRNA).
     J Control Release, 119(3): 349-59. [Abstract] [Full-text]
232. In vitro and in vivo protein delivery from in situ forming poly(ethylene glycol)-poly(lactide) hydrogels.
     J Control Release, 119(3): 320-7. [Abstract] [Full-text]
233. Phosphatidylcholine embedded microemulsions: physical properties and improved Caco-2 cell permeability.
     J Control Release, 119(3): 279-90. [Abstract] [Full-text]
234. Photocrosslinking of dextran and polyaspartamide derivatives: a combination suitable for colon-specific drug delivery.
     J Control Release, 119(3): 328-38. [Abstract] [Full-text]
235. Recombinant gelatin hydrogels for the sustained release of proteins.
     J Control Release, 119(3): 301-12. [Abstract] [Full-text]
236. Synthesis, biodistribution and excretion of radiolabeled poly(2-alkyl-2-oxazoline)s.
     J Control Release, 119(3): 291-300. [Abstract] [Full-text]
237. Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue.
     Pediatr Blood Cancer, 49(1): 34-40. [Abstract] [Full-text]
238. Synthesis of poly(sebacic anhydride)-indomethacin controlled release composites via supercritical carbon dioxide assisted impregnation.
     Int J Pharm, 338(1): 191-7. [Abstract] [Full-text]
239. Development of pH- and time-dependent oral microparticles to optimize budesonide delivery to ileum and colon.
     Int J Pharm, 338(1): 238-47. [Abstract] [Full-text]
240. Study on liposomalization of zinc-coproporphyrin I as a novel drug in photodynamic therapy.
     Int J Pharm, 338(1): 306-9. [Abstract] [Full-text]
241. 5-Fluorouracil plasma levels and biodegradation of subcutaneously injected drug-loaded microspheres prepared by spray-drying poly(D,L-lactide) and poly(D,L-lactide-co-glycolide) polymers.
     Int J Pharm, 338(1): 180-90. [Abstract] [Full-text]
242. Physico-chemical characterization of nanocapsule polymeric wall using fluorescent benzazole probes.
     Int J Pharm, 338(1): 297-305. [Abstract] [Full-text]
243. Potential application of Metolose in a thermoresponsive transdermal therapeutic system.
     Int J Pharm, 338(1): 15-20. [Abstract] [Full-text]
244. Fabrication of drug-loaded biodegradable microcapsules for controlled release by combination of solvent evaporation and layer-by-layer self-assembly.
     Int J Pharm, 338(1): 165-73. [Abstract] [Full-text]
245. Controlled protein release from electrospun biodegradable fiber mesh composed of poly(epsilon-caprolactone) and poly(ethylene oxide).
     Int J Pharm, 338(1): 276-83. [Abstract] [Full-text]
246. Preparation and in vitro characterization of carrier erythrocytes for vaccine delivery.
     Int J Pharm, 338(1): 70-8. [Abstract] [Full-text]
247. One-year endometrial safety evaluation of a continuous combined transdermal matrix patch delivering low-dose estradiol-norethisterone acetate in postmenopausal women.
     Maturitas, 57(2): 171-81. [Abstract] [Full-text]
248. Hormonal therapy is associated with a lower prevalence of breast arterial calcification on mammography.
     Maturitas, 57(2): 154-60. [Abstract] [Full-text]
249. The effects of black cohosh therapies on lipids, fibrinogen, glucose and insulin.
     Maturitas, 57(2): 195-204. [Abstract] [Full-text]
250. Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: long-term follow-up.
     Maturitas, 57(2): 210-3. [Abstract] [Full-text]
251. Endometrial safety after 5 years of continuous combined transdermal estrogen and intrauterine levonorgestrel delivery for postmenopausal hormone substitution.
     Maturitas, 57(2): 205-9. [Abstract] [Full-text]
252. Pharmacist medication assessments in a surgical preadmission clinic.
     Arch Intern Med, 167(10): 1034-40. [Abstract] [Full-text]
253. Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial.
     Br J Cancer, 96(11): 1633-8. [Abstract] [Full-text]
254. A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group.
     Br J Cancer, 96(11): 1639-43. [Abstract] [Full-text]
255. Trichodysplasia spinulosa associated with chemotherapy for acute lymphocytic leukaemia.
     Australas J Dermatol, 48(2): 110-4. [Abstract] [Full-text]
256. Castleman disease.
     Curr Opin Hematol, 14(4): 354-9. [Abstract] [Full-text]
257. Colon cancer risk and different HRT formulations: a case-control study.
     BMC Cancer, 7: 76. [Abstract] [Full-text]
258. Multifunctionalized polymer microcapsules: novel tools for biological and pharmacological applications.
     Small, 3(6): 944-55. [Abstract] [Full-text]
259. Serum cellular fibronectin and matrix metalloproteinase-9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic therapy in acute ischemic stroke: a multicenter confirmatory study.
     Stroke, 38(6): 1855-9. [Abstract] [Full-text]
260. Size matters: hemorrhage volume as an objective measure to define significant intracranial hemorrhage associated with thrombolysis.
     Stroke, 38(6): 1799-804. [Abstract] [Full-text]
261. Arterial baroreflex: a novel target for preventing stroke in rat hypertension.
     Stroke, 38(6): 1916-23. [Abstract] [Full-text]
262. Thrombolysis for ischemic stroke in children: data from the nationwide inpatient sample.
     Stroke, 38(6): 1850-4. [Abstract] [Full-text]
263. Nanometer-sized molybdenum-iron oxide capsule-surface modifications: external and internal.
     Small, 3(6): 986-92. [Abstract] [Full-text]
264. Medicating young or very young patients--part II.
     Orthop Nurs, 26(3): 194-201; quiz 202-3. [Abstract] [Full-text]
265. Chemotherapy delivery issues in central nervous system malignancy: a reality check.
     J Clin Oncol, 25(16): 2295-305. [Abstract] [Full-text]
266. Economic analysis of NCIC CTG JBR.10: a randomized trial of adjuvant vinorelbine plus cisplatin compared with observation in early stage non-small-cell lung cancer--a report of the Working Group on Economic Analysis, and the Lung Disease Site Group, National Cancer Institute of Canada Clinical Trials Group.
     J Clin Oncol, 25(16): 2256-61. [Abstract] [Full-text]
267. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial.
     J Clin Oncol, 25(16): 2218-24. [Abstract] [Full-text]
268. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group.
     J Clin Oncol, 25(16): 2212-7. [Abstract] [Full-text]
269. Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study.
     J Clin Oncol, 25(16): 2178-83. [Abstract] [Full-text]
270. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
     N Engl J Med, 356(22): 2271-81. [Abstract] [Full-text]
271. Targeting sensory axon regeneration in adult spinal cord.
     J Neurosci, 27(22): 6068-78. [Abstract] [Full-text]
272. Preoperative mechanical preparation of the colon: the patient's experience.
     BMC Surg, 7: 5. [Abstract] [Full-text]
273. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.
     J Clin Oncol, 25(16): 2198-204. [Abstract] [Full-text]
274. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07.
     J Clin Oncol, 25(16): 2205-11. [Abstract] [Full-text]
275. Hormone replacement therapy and breast cancer in former users of oral contraceptives--The Norwegian Women and Cancer study.
     Int J Cancer, 121(3): 645-8. [Abstract] [Full-text]

© 2004-2012 Chemotherapy Research Today. All Rights Reserved.